Scientific Advisory Board
Autoimmune Disease Scientific Advisory Board
Mary K. Crow, M.D.
Dr. Crow is the Benjamin M. Rosen Chair in Immunology and Inflammation Research Professor of Medicine and Director of Rheumatology Research and Autoimmunity and Inflammation Program Hospital for Special Surgery, New York, NY.
Richard Furie, M.D.
Dr. Furie is Chief, Division of Rheumatology and Allergy-Clinical Immunology; Director, The Systemic Lupus Erythematosus and Autoimmune Disease Treatment Center; Director, The Program in Novel Therapeutics, North Shore Long Island Jewish Health System, Lake Success, NY; and Professor of Medicine, Albert Einstein College of Medicine, Bronx, NY.
Douglas Golenbock, M.D.
Dr. Golenbock is Professor of Medicine, Molecular Genetics & Microbiology and Chief, Division of Infectious Diseases & Immunology, University of Massachusetts Medical School, Worcester, MA.
Andrew D Luster, M.D., Ph.D.
Dr. Luster is Chief, Division of Rheumatology, Allergy and Immunology; Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA; and Persis, Cyrus and Marlow B. Harrison Professor of Medicine (Immunology), Harvard Medical School, Boston, MA.
Ann Rothstein, Ph.D.
Dr. Rothstein is Professor of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA.
David Pisetsky, M.D., Ph.D.
Dr. Pisetsky is Professor of Medicine and Immunology, Duke University Medical Center, Durham, NC.
Vibeke Strand, M.D.
Dr. Strand is Clinical Professor, Adj., Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA.
Michael Weinblatt, M.D.
Dr. Weinblatt is the John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School, Boston, MA and Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA.
Jonathan Wilkin, M.D.
Dr. Wilkin was the founding director of the Division of Dermatology and Dental Products at the US Food and Drug Administration and has previously been a member of the FDA's Dermatology Drugs Advisory Committee.
